Core Viewpoint - The company reported a decline in net profit for the first quarter of 2025, primarily due to changes in the VAT calculation method for in vitro diagnostic reagents, leading to a decrease in operating revenue compared to the same period last year [4][5][6]. Financial Data Summary - The first quarter financial report is unaudited [3]. - The company's net profit decreased compared to the same period last year, attributed to the adjustment of the VAT calculation method for in vitro diagnostic reagents, resulting in a decline in operating revenue [4]. - The net cash flow from operating activities decreased by 134.97% compared to the same period last year, mainly due to reduced accounts receivable collections from the subsidiary [4]. Shareholder Information - As of the end of the reporting period, the company held 1,291,428 shares in its repurchase account, accounting for 3.23% of the total share capital [6]. Board Meeting Resolutions - The company held its 11th meeting of the second board on April 28, 2025, where several resolutions were passed, including the approval of the 2024 annual general manager's work report and the 2024 annual board work report [9][11]. - The board also approved the 2024 financial settlement report and the 2024 annual report, which will be submitted for shareholder approval [13][16]. Profit Distribution Plan - The company proposed a cash dividend of 1.00 yuan per 10 shares (including tax), with a total distribution amounting to 3,870,857.20 yuan based on the adjusted total shares [99][100]. - The profit distribution plan is subject to approval at the 2024 annual general meeting [101][103]. Related Transactions - The company plans to use idle funds to purchase financial products from Jiangnan Rural Commercial Bank, with a maximum balance of 50 million yuan and a term not exceeding 12 months [63][64]. - This transaction has been approved by the board and will be submitted for shareholder approval [79][80]. Audit Firm Appointment - The company intends to reappoint Lixin Certified Public Accountants as its auditor for the 2025 fiscal year, pending shareholder approval [86][87]. - Lixin has a strong track record and has provided audit services to numerous listed companies [88][89].
上海仁度生物科技股份有限公司 2025年第一季度报告